A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Multiple Rising Doses of TAK-137 in Adult Subjects With Attention-Deficit/Hyperactivity Disorder

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Multiple Rising Doses of TAK-137 in Adult Subjects With Attention-Deficit/Hyperactivity Disorder

Discontinued
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2016

At a glance

  • Drugs TAK 137 (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions
  • Sponsors Takeda
  • Most Recent Events

    • 13 Jan 2015 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 16 Oct 2014 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 15 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top